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Paris, FranceFIGURE 1. Application of trial sequential analysis to interpret the results of 8 placebo-controlled tri-
als evaluating preoperative n-3 polyunsaturated fatty acids to prevent postoperative atrial fibrillation in
heart surgery (A and B, expected 15% and -20% relative risk reductions, respectively). In both graphs,
the z curve (blue) is composed of consecutive segments that correspond to individual trials; trials are
plotted in chronologic order from left to right. The x-axis indicates the cumulative number of patients;References
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number of 2687 included patients (8 trials), the curve is still in an inconclusive area, because none
of the boundaries of superiority or inferiority or futility have been reached. The information-size anal-
ysis estimates that at least 8614 or 4763 patients (A and B, respectively) would be needed to reach a
conclusion in terms of superiority or inferiority or futility. Red lines are the boundaries for superiority
or inferiority; green lines are the boundaries for futility; horizontal brown lines indicate the traditional
limits of statistical significance (z ¼ 1.96 or 1.96). T, Treatment, C, control.SUPPLEMENTATION OF N-3
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SURGERY
To the Editor:
The debate on the effectiveness of
n-3 polyunsaturated fatty acids
(PUFAs) in cardiovascular disease
has recently been fueled by the
publication of 3 meta-analyses.1-3
Furthermore, attempts to apply trial
sequential analysis (TSA) to these
issues have also contributed to the
debate.4,5
With regard to secondary preven-
tion of cardiovascular disease, the
meta-analysis by Kwak and col-
leagues1 found no proof ofThe Journaleffectiveness for PUFAs. Later, a
TSA that was based on the same data
provided a stronger negative conclu-
sion in terms of proof of no effective-
ness (futility).4 Likewise, with regard
to the role of PUFAs to prevent atrial
fibrillation, a meta-analysis showing
no effectiveness was published,2 fol-
lowed by a TSA indicating futility.5
In this framework, the meta-
analysis by Costanzo and associates3
recently published in the Journal has
been focused on the preoperative sup-
plementation of PUFAs to prevent
postoperative atrial fibrillation inof Thoracic and Cardiovascular Surgeheart surgery. The results of this
meta-analysis were borderline,
because most effectiveness indices
were at the limits of statistical
significance.
In an attempt to clarify the uncer-
tainty surrounding the effectiveness
of PUFAs for this indication, we un-
dertook a TSA aimed at reexamining
the same 8 trials evaluated by Cos-
tanzo and associates.3 Our analysis
considered the end point of postopera-
tive atrial fibrillation. Main assump-
tions included 2-sided testing, risk of
type 1 error of 5%, and power ofry c Volume 146, Number 4 991
Letters to the Editor80%. The intervention effect was set
at an anticipated 15% or 20% relative
risk reduction, with the event rate in
the control group assumed to be
30% (equal to the overall rate in the
8 control groups). As usual, the main
result of TSA was expressed through
the graph of cumulative z curve.
With reference to this graph, the
boundaries for concluding superiority
or inferiority or futility were calcu-
lated according to the O’Brien-
Fleming a-spending function. Our
analysis was done with a specific sta-
tistical software package (TSA
Viewer; Copenhagen Trial Unit,
Copenhagen, Denmark).
Application of TSA to these 8 ran-
domized trials generated an inconclu-
sive result (Figure 1). In particular, our
analysis estimated that the optimal in-
formation size would be 8614 or 4763
patients (according to the assumptions
of relative risk reduction of 15% or
20%, respectively). At the cumulative
number of 2687 patients (those
included in the 8 trials published
thus far), the z curve remained, in
both graphs, quite far from intercept-
ing the boundary of superiority but at
the same time did not reach the futility
area.
In the light of the current evidence,
the conclusion that PUFAs are effec-
tive for this clinical indication is not
justified; on the other hand, neither
can the conclusion of a proven inef-
fectiveness of PUFAs be made. Unless
further positive trial results are made
available, uncertainty remains
regarding the effectiveness of PUFAs
for this indication. Overall, if one con-
siders that a clear proof of ineffective-
ness has been obtained for two other
important indications of PUFAs,4,5
the overall picture of the therapeutic
role of these agents seems to be
extremely weak.
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In their letter, Messori and col-
leagues described their performance
of a trial sequential analysis (TSA) to
interpret better the results of a meta-
analysis we recently published in the
Journal, ‘‘Prevention of postoperative
atrial fibrillation in open heart surgery
patients by preoperative supplementa-
tion of n-3 polyunsaturated fatty acids:
An updated meta-analysis.’’1 After
application of TSA to the same 8 trials
included in our study1 and another
meta-analysis on the same topic,2 they
state that the results are inconclusive
but tendmore toward proof of no effec-
tiveness of n-3 polyunsaturated fatty
acid (PUFA) supplementation for pre-
venting postoperative atrial fibrillation
(POAF) after heart surgery.
Although the findings of Messori
and colleagues appear to be reliable,ardiovascular Surgery c October 2013one should consider that in our meta-
analysis on the effect of preoperative
n-3 PUFA supplementation in POAF
prevention after cardiac surgery,1
several sources of heterogeneity
were found, in particular the type of
surgery or of placebo. For this reason,
we performed both sensitivity and
subgroup analyses to investigate the
source of heterogeneity among studies
and focused on the type of cardiac
surgery.1 The novelty of our meta-
analysis was the effect of the
preoperative supplementation of n-3
PUFAs on POAF, in a specific heart
surgical procedure such as coronary
artery bypass grafting (CABG). Data
on patients who underwent isolated
CABG were extracted from 7 studies
(1028 patients), and a significant pro-
tection of 34% was observed with a
fixed-effects model (odds ratio 0.66,
95% confidence interval 0.50–0.87;
P ¼ .003; I2 ¼ 26%; P ¼ 0.23).1 We
concluded that the preoperative sup-
plementation of n-3 PUFAs to patients
undergoing isolated CABG signifi-
cantly prevents the occurrence of
POAF.
We have now reexamined, with the
TSA suggested by Messori and col-
leagues, the 7 trials performed on
isolated CABG. This analysis was
performed according to the O’Brien-
Fleming a-spending function and
considering the assumptions of the
2-sided testing, the risk of type 1 error
as 5%, the power as 80%, the event
frequency assigned to the controls as
33.5% (the pooled frequency in the
7 control groups, 172 POAF events
in 513 patients), and the relative risk
reduction of 25% (TSA Viewer;
Copenhagen Trial Unit, Copenhagen,
Denmark).2,3 Figure 1 shows the
main result of TSA, expressed through
the graph of the cumulative z curve
and the threshold for a statistically
significant treatment effect. The cu-
mulative z curve crosses the trial
sequential monitoring boundary for
benefit, indicating a beneficial effect
of almost 25% relative risk reduction
of POAF in the intervention arm.
